Home Newsfeeds Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

News

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the first participant in Italy has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

byCharles Gross

March 8, 2023

1 minute read

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

News

Amkor Announces U.S. Advanced Packaging And Test Facility; Amkor Projects To Invest ~$2B And Employ ~2,000 People At The New Facility

By Benzinga Newsdesk

November 30, 10:10 AM

Amkor enables a resilient domestic semiconductor supply chain with the construction of its new advanced packaging facility in ArizonaAmkor Technology, Inc. (NASDAQ:AMKR), a leading provider of semiconductor packaging and

AAPL

Here’s How Much $100 Invested In ON Semiconductor 5 Years Ago Would Be Worth Today

By Benzinga Insights

February 21, 2:02 PM

ON Semiconductor (NASDAQ:ON) has outperformed the market over the past 5 years by 19.32% on an annualized basis…

China Tensions Are Top Of Mind For Biden’s Weeklong Asia Tour: ‘We Are Not Going To Arm-Twist’

By Natan Ponieman

May 16, 3:08 PM

Tensions building up abroad seem to be urgent enough for President Joe Biden to leave the Oval Office…

GXC

Cogent Biosciences Priced Upsized 12.5M Share Public Offering of Shares of Common Stock @$12/Share

By Charles Gross

June 7, 5:35 AM

Cogent Biosciences, Inc. (NASDAQ:COGT) announced the pricing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, offered at a public offering price

COGT

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Related Posts

Amkor Announces U.S. Advanced Packaging And Test Facility; Amkor Projects To Invest ~$2B And Employ ~2,000 People At The New Facility

Here’s How Much $100 Invested In ON Semiconductor 5 Years Ago Would Be Worth Today

China Tensions Are Top Of Mind For Biden’s Weeklong Asia Tour: ‘We Are Not Going To Arm-Twist’

Cogent Biosciences Priced Upsized 12.5M Share Public Offering of Shares of Common Stock @$12/Share